Psychometric validation of symptom severity measures in irritable bowel syndrome with constipation

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 3, 2014, Pages 298-308

  Williams, V S L ^a   Nelson, L M ^a   Fehnel, S E ^a   Macdougall, J ^b   Carson, R T ^c   Tourkodimitris, S ^c   Kurtz, C ^b   Baird, M J ^b   Johnston, J M ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b Ironwood Pharmaceuticals   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINACLOTIDE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INSTRUMENT VALIDATION; IRRITABLE BOWEL SYNDROME WITH CONSTIPATION SYMPTOM SEVERITY MEASURE; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; PEPTIDES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; SELF REPORT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904070311     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12830     Document Type: Article

References (23)

1. Longstreth GF, Thompson WG, Chey WD, et al,. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Sandler RS,. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990; 99: 409-15.
3. Andrews EB, Eaton SC, Hollis KA, et al,. Prevalence and demographics of irritable bowel syndrome: results from a large Web-based survey. Aliment Pharmacol Ther 2005; 22: 935-42.
4. Hungin AP, Chang L, Locke GR, et al,. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365-75.
5. Lovell RM, Ford AC,. Global prevalence of, and risk factors for, irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
6. US Department of Health and Human Services. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. December 2009. Available at: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed March 24, 2010.
7. Fehnel SE, Ervin CM, Lewis BE, Carson RT, Johnston JM,. Identifying endpoints for irritable bowel syndrome (IBS) clinical trials: incorporating the patient's voice. Poster presented at the 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); November 2010. Prague, Czech Republic.
8. Johnston JM, Kurtz CB, MacDougall JE, et al,. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010; 139: 1877-86.
9. Chey WD, Lembo AJ, Lavins BJ, et al,. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702-12.
10. Rao S, Lembo AJ, Shiff SJ, et al,. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-24.
11. Drossman DA, Corzziari E, Talley NJ, et al,. Rome II: The Functional Gastrointestinal Disorders, 2nd ed. Degnon Associates: McLean VA, 2000.
12. Heaton KW, O'Donnell LJD,. An office guide to whole-gut transit time: patient's recollection of their stool form. J Clin Gastroenterol 1994; 19: 28-30.
13. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: irritable bowel syndrome-clinical evaluation of drugs for treatment. 2012. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf. Accessed April 30, 2013.
14. Patrick DL, Drossman DA, Frederick IO, et al,. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-11.
15. Francis CY, Morris J, Whorwell PJ,. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402.
16. Snaith RP, Zigmond AS,. The Hospital Anxiety and Depression Scale Manual. Windsor, Berkshire, England: Nfer-Nelson, 1994.
17. Zigmond AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
18. SAS Institute, Inc. SAS Proprietary Software, version 9.2. Cary, NC: SAS Institute, Inc., 2008.
19. Muthén LK, Muthén BO,. Mplus User's Guide, 6th ed. Los Angeles: Muthén & Muthén, 1998 -2010.
20. Carson RT, Nelson LM, Williams V, MacDougall JE, Johnston JM,. Psychometric evaluation of patient-reported outcome measures for assessing IBS-C symptom severity and global change: results from a phase 2b study of linaclotide (poster #681). Poster presented at the American College of Gastroenterology 2009 Scientific Meeting; October 2009. San Diego CA.
21. Nunnally JC, Bernstein IH,. Psychometric Theory, 3rd ed. New York: McGraw-Hill, 1994.
22. Cohen J,. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
23. Guyatt GH, Walter SD, Norman G,. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40: 171-8.